

PROVIDER BULLETIN

PROVIDER INFORMATION



December 1, 2022

Medical Policy Updates: Coupe Health and Self-Funded Benefit Plans managed by Blue Cross and Blue Shield of Alabama

Participating providers are invited to submit for consideration scientific, evidence-based information, professional consensus opinions, and other information supported by medical literature relevant to our draft policies for Coupe Health and Self-Funded benefit plans managed by Blue Cross and Blue Shield of Alabama.

The draft policies are available for physician comment for 45 days from the posting date found on the document. At the conclusion of the 45 days, policies will go into effect. Make sure your voice is heard by providing feedback directly to us.

How to Submit Comments on Draft Medical Policies

[Complete our medical policy feedback form](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback) online at <https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback> or send comments and supporting documentation to us by mail or fax:

Birmingham Service Center
Attn: Health Management - Medical Policy
P.O. Box 10527
Birmingham, AL 35202
Fax: 205-220-0878

Draft Medical Policies

Draft medical policies can be found at [Policies & Guidelines \(exploremyplan.com\)](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback)

Policy #	Policy Title
MP-215	Amino Acid-Based Elemental Formulas
MP-681	Biofeedback

Draft Provider-Administered Drug Policies

Draft provider-administered drug policies can be found at [Policies & Guidelines \(exploremyplan.com\)](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback) and [Policies & Guidelines \(exploremyplan.com\)](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback)

Policy #	Policy Title
PH-403	Immunoglobulin Therapy
PH-90677	Skysona® (elivaldogene autotemcel)
PH-90674	Spevigo® (spesolimab)

Policy #	Policy Title
PH-90673	Xenpozyme™ (olipudase alfa)
PH-90018	Beriner® (C1 Esterase Inhibitor, Human)
PH-90028	Cimzia® (certolizumab pegol)
PH-90347	Fasenra® (benralizumab)
PH-90260	Nucala® (mepolizumab)
PH-90207	Ruconest® (C1 Esterase Inhibitor [recombinant])
PH-90146	Xolair® (omalizumab)
PH-90002	Actemra® (tocilizumab)
PH-90497	Beovu® (brolicizumab-dbl)
PH-90273	Cinqair® (reslizumab)
PH-90660	Enjaymo™ (sutimlimab-jome)
PH-90026	Eylea® (aflibercept)
PH-90061	Hyaluronic Acid Derivatives: Durolane®, Euflexxa™, Gel-One®, GelSyn-3™, GenVisc 850®, Hyalgan™, Hymovis®, Monovisc®, Orthovisc™, Supartz/Supartz FX™, Synvisc™, Synvisc-One™, Triluron™, TriVisc™, VISCO-3™, & sodium hyaluronate 1%
PH-90104	Infliximab: Remicade®; Inflectra™; Renflexis™; Avsola™, Infliximab*
PH-90167	Kalbitor® (ecallantide)
PH-90223	Lemtrada® (alemtuzumab)
PH-90080	Leuprolide Suspension: Lupron Depot®, Lupron Depot-Ped®, Eligard®, Fensolvi®, Camcevi™
PH-90081	Macugen® (pegaptanib)
PH-90298	Ocrevus™ (ocrelizumab)
PH-90176	Simponi Aria® (golimumab)
PH-90634	Susvimo™ (ranibizumab)
PH-90131	Trelstar® (triptorelin)